Back to results
US 2021/0241876 A1Published application
Insulin and pramlintide delivery systems, methods, and devices
AssigneeEli Lilly and Company
InventorAhmad Mohamad HAIDAR
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to systems and methods for controlling physiological glucose concentrations in a patient.
Claims33
A system to control glucose in a patient, the system comprising:
- a medication delivery device configured to deliver medication to the patient;
- and
- a controller in communication with the medication delivery device and including control logic operative to calculate a bolus delivery schedule comprising an initial bolus delivery amount and a delayed bolus delivery amount, wherein the initial bolus delivery amount relative to the delayed bolus delivery amount is based, at least in part, on a pre-meal glucose level.
A system to control glucose in a patient, the system comprising:
- a medication delivery device configured to deliver medication to the patient;
- and
- means for calculating a bolus delivery schedule comprising an initial bolus delivery amount and a delayed bolus delivery amount based, at least in part, on a pre-meal glucose level.
33-70. (canceled)
Dependencies are inferred from the claim text.